清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma

医学 内科学 肝细胞癌 科克伦图书馆 荟萃分析 肝功能 肿瘤科 不利影响 随机对照试验 指南 病理
作者
Enrui Xie,Yee Hui Yeo,Bernhard Scheiner,Yue Zhang,Atsushi Hiraoka,Xinxing Tantai,Petros Fessas,Tiago B. R. Castro,Antonio D’Alessio,Claudia Angela Maria Fulgenzi,Shuo Xu,Hong‐Ming Tsai,Swetha Kambhampati,Wenjun Wang,Bridget P. Keenan,Xu Gao,Zixuan Xing,Matthias Pinter,Yih‐Jyh Lin,Zhanjun Guo
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:9 (10): 1423-1423 被引量:63
标识
DOI:10.1001/jamaoncol.2023.3284
摘要

Importance Immune checkpoint inhibitors (ICIs) are increasingly used in patients with advanced hepatocellular carcinoma (HCC). However, data on ICI therapy in patients with advanced HCC and impaired liver function are scarce. Objective To conduct a systematic review and meta-analysis to determine the efficacy and safety of ICI treatment for advanced HCC with Child-Pugh B liver function. Data Sources PubMed, Embase, Web of Science, and Cochrane Library were searched for relevant studies from inception through June 15, 2022. Study Selection Randomized clinical trials, cohort studies, or single-group studies that investigated the efficacy or safety of ICI therapy for Child-Pugh B advanced HCC were included. Data Extraction and Synthesis The Preferred Reporting Items for Systematic Reviews and Meta-Analysis guideline was followed to extract data. A random-effects model was adopted if the heterogeneity was significant ( I 2 > 50%); otherwise, a fixed-effect model was used. Main Outcomes and Measures The objective response rate (ORR) and overall survival (OS) were considered to be the primary efficacy outcomes of ICI treatment for Child-Pugh B advanced HCC, and the incidence of treatment-related adverse events (trAEs) was set as the primary measure for the safety outcome. Results A total of 22 studies including 699 patients with Child-Pugh B and 2114 with Child-Pugh A advanced HCC comprised the analytic sample (median age range, 53-73 years). Upon pooled analysis, patients treated with ICIs in the Child-Pugh B group had an ORR of 14% (95% CI, 11%-17%) and disease control rate (DCR) of 46% (95% CI, 36%-56%), with a median OS of 5.49 (95% CI, 3.57-7.42) months and median progression-free survival of 2.68 (95% CI, 1.85-3.52) months. The rate of any grade trAEs in the Child-Pugh B group was 40% (95% CI, 34%-47%) and of grade 3 or higher trAEs was 12% (95% CI, 6%-23%). Compared with the Child-Pugh A group, the ORR (odds ratio, 0.59; 95% CI, 0.43-0.81; P < .001) and DCR (odds ratio, 0.64; 95% CI, 0.50-0.81; P < .001) were lower in the Child-Pugh B group. Child-Pugh B was independently associated with worse OS in patients with advanced HCC treated with ICIs (hazard ratio, 2.72 [95% CI, 2.34-3.16]; adjusted hazard ratio, 2.33 [95% CI, 1.81-2.99]). However, ICIs were not associated with increased trAEs in the Child-Pugh B group. Conclusions and Relevance The findings of this systematic review and meta-analysis suggest that although the safety of ICI treatment was comparable between patients with HCC with vs without advanced liver disease and the treatment resulted in a significant number of radiologic responses, survival outcomes are still inferior in patients with worse liver function. More study is needed to determine the effectiveness of ICI treatment in this population.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
结实的易真完成签到,获得积分10
5秒前
丰富的从雪完成签到,获得积分10
19秒前
25秒前
踏实的雁兰完成签到,获得积分10
27秒前
精明夜安完成签到,获得积分10
28秒前
大方的钥匙完成签到,获得积分10
40秒前
bluemoon完成签到,获得积分20
1分钟前
Orange的应助被好德小饼干采纳,获得10
1分钟前
听话的尔竹完成签到,获得积分10
1分钟前
1分钟前
1分钟前
bluemoon发布了新的文献求助10
1分钟前
无极微光的应助被王磊磊0811采纳,获得20
1分钟前
1分钟前
灵巧笑旋完成签到,获得积分10
1分钟前
拼搏静槐完成签到,获得积分10
1分钟前
传奇3的应助被好德小饼干采纳,获得10
1分钟前
超帅晓槐完成签到,获得积分10
1分钟前
1分钟前
无辜秋尽完成签到,获得积分10
1分钟前
自信的镜子完成签到,获得积分10
1分钟前
Hello的应助被科研通管家采纳,获得10
2分钟前
脑洞疼的应助被科研通管家采纳,获得10
2分钟前
SciGPT的应助被科研通管家采纳,获得10
2分钟前
车厘子完成签到,获得积分10
2分钟前
阔达翠霜完成签到,获得积分10
2分钟前
隐形的芷文完成签到,获得积分10
2分钟前
开心的筮完成签到,获得积分10
2分钟前
能干念波完成签到 ,获得积分10
2分钟前
秀丽颤完成签到,获得积分10
2分钟前
迷路芷荷完成签到,获得积分10
2分钟前
披着羊皮的狼完成签到 ,获得积分0
2分钟前
虚心从蓉完成签到,获得积分10
3分钟前
mtenxx完成签到,获得积分10
3分钟前
懦弱的绿蝶完成签到,获得积分10
3分钟前
3分钟前
mtenxx发布了新的文献求助10
3分钟前
高兴的梦槐完成签到,获得积分10
3分钟前
温柔晓筠完成签到,获得积分10
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158935
求助须知:如何正确求助?哪些是违规求助? 9554526
关于积分的说明 21719385
捐赠科研通 7748467
什么是DOI,文献DOI怎么找? 3427107
关于科研通互助平台的介绍 2552013
邀请新用户注册赠送积分活动 2471370